The purpose of this study is to determine the safety and tolerability of XmAb657 in healthy participants and participants with autoimmune diseases. Participants will be given XmAb657 subcutaneously (SC) by injection under the skin.
This is a Phase 1 study to determine the safety, tolerability, pharmacokinetic (PK), and pharmacodynamics (PD), and immunogenicity of XmAb657 in healthy adult participants and participants with autoimmune diseases.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
60
Biological
Xencor Investigative Site
Melbourne, Australia
RECRUITINGPercentage of participants with treatment emergent adverse events (TEAEs) and serious adverse events (SAEs)
Time frame: Through Week 52
Serum concentration of XmAb657
Time frame: Through Week 52
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.